We are live on ! Find out more
YARW

Yarrow Bioscience, Inc. Common Stock

37 hedge funds and large institutions have $1.84M invested in Yarrow Bioscience, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 5 increasing their positions, 6 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 3737 (0)

0% less ownership

Funds ownership: 0.02%0.02% (-0%)

0% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 6

17% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 6

43% less capital invested

Capital invested by funds: $3.25M → $1.84M (-$1.41M)

Holders
37
Holders Change
Holders Change %
0%
% of All Funds
0.64%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
6
Increased
5
Reduced
6
Closed
6
Calls
Puts
Net Calls
Net Calls Change

YARW Hedge Fund Activity: Q3 2022 in Review

37 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Yarrow Bioscience, Inc. Common Stock (YARW) for Q3 2022, worth a combined $1.84M — down 43% from $3.25M a quarter earlier.

Fund positioning in YARW was balanced in Q3 2022: 6 funds opened new positions, 6 closed out, 5 added to existing stakes and 6 trimmed.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $30.7K. The largest seller was Vanguard Group, cutting an estimated $53.8K.

  • 37 institutional investors held Yarrow Bioscience, Inc. Common Stock (YARW) as of Q3 2022, unchanged from Q2 2022.
  • Funds reported $1.84M of Yarrow Bioscience, Inc. Common Stock stock for Q3 2022, down 43% quarter-over-quarter.
  • 6 funds opened new Yarrow Bioscience, Inc. Common Stock positions in Q3 2022 and 6 closed out, a net change of 0 holders.
  • The largest Yarrow Bioscience, Inc. Common Stock buyer in Q3 2022 was Citadel Advisors, an estimated $30.7K added.
  • The largest Yarrow Bioscience, Inc. Common Stock seller in Q3 2022 was Vanguard Group, an estimated $53.8K sold.

Based on aggregated 13F filings for Q3 2022.